# A Study to Assess the Efficacy and Safety of ABTL0812

> **NCT03366480** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ability Pharmaceuticals SL** · enrollment: 103 (actual)

## Conditions studied

- Endometrial Cancer
- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ABTL0812 in combination with paclitaxel and carboplatin

## Key facts

- **NCT ID:** NCT03366480
- **Lead sponsor:** Ability Pharmaceuticals SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-11-15
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366480, "A Study to Assess the Efficacy and Safety of ABTL0812". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03366480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*